[go: up one dir, main page]

EP2970138A4 - Dérivés de pyrazole et leurs utilisations - Google Patents

Dérivés de pyrazole et leurs utilisations

Info

Publication number
EP2970138A4
EP2970138A4 EP14765081.6A EP14765081A EP2970138A4 EP 2970138 A4 EP2970138 A4 EP 2970138A4 EP 14765081 A EP14765081 A EP 14765081A EP 2970138 A4 EP2970138 A4 EP 2970138A4
Authority
EP
European Patent Office
Prior art keywords
pyrazole derivatives
pyrazole
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP14765081.6A
Other languages
German (de)
English (en)
Other versions
EP2970138B1 (fr
EP2970138A1 (fr
Inventor
Donald R Branch
Lakshmi P Kotra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Canadian Blood Services
University Health Network
Original Assignee
Canadian Blood Services
University Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canadian Blood Services, University Health Network filed Critical Canadian Blood Services
Publication of EP2970138A4 publication Critical patent/EP2970138A4/fr
Publication of EP2970138A1 publication Critical patent/EP2970138A1/fr
Application granted granted Critical
Publication of EP2970138B1 publication Critical patent/EP2970138B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP14765081.6A 2013-03-13 2014-03-12 Dérivés de pyrazole et leurs utilisations Active EP2970138B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361778884P 2013-03-13 2013-03-13
US201361778865P 2013-03-13 2013-03-13
PCT/CA2014/050222 WO2014138979A1 (fr) 2013-03-13 2014-03-12 Dérivés de pyrazole et leurs utilisations

Publications (3)

Publication Number Publication Date
EP2970138A4 true EP2970138A4 (fr) 2016-01-20
EP2970138A1 EP2970138A1 (fr) 2016-01-20
EP2970138B1 EP2970138B1 (fr) 2019-01-16

Family

ID=51535708

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14765081.6A Active EP2970138B1 (fr) 2013-03-13 2014-03-12 Dérivés de pyrazole et leurs utilisations

Country Status (5)

Country Link
US (2) US10130609B2 (fr)
EP (1) EP2970138B1 (fr)
CA (1) CA2903612C (fr)
DK (1) DK2970138T3 (fr)
WO (1) WO2014138979A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024000067A1 (fr) * 2022-06-28 2024-01-04 Canadian Blood Services Dérivés de pyrazole pour l'inhibition de la phagocytose

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011042798A1 (fr) * 2009-10-08 2011-04-14 Incozen Therapeutics Pvt. Ltd. Dérivés de pyrazole en tant que modulateurs du canal calcique activé par la libération de calcium et méthode de traitement pour le cancer du poumon à cellules non petites
WO2011092140A1 (fr) * 2010-01-27 2011-08-04 Boehringer Ingelheim International Gmbh Composés pyrazole comme antagonistes du crth2

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4171367A (en) 1977-02-18 1979-10-16 Abbott Laboratories Pyrazolyl amino imidazolines
US5006520A (en) 1987-10-13 1991-04-09 Yoshitomi Pharmaceutical Industries, Ltd. Fused pyrazole compounds and pharmaceutical use thereof
DE10038029A1 (de) 2000-08-02 2002-02-14 Henkel Kgaa Mittel zum Färben von keratinhaltigen Fasern
MXPA05001096A (es) 2002-07-29 2005-11-23 Rigel Pharmaceuticals Inc Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina.
ES2244326B1 (es) * 2004-04-05 2007-02-16 Laboratorios Del Dr. Esteve, S.A. Combinacion de substancias activas.
EP1768662A2 (fr) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Immuno-potentialisateurs a petites molecules et analyses visant a detecter leur presence
KR100635541B1 (ko) 2004-10-12 2006-10-18 경북대학교 산학협력단 신규한 염증성 질환의 예방 또는 치료용 약학적 조성물
WO2006057448A1 (fr) * 2004-11-26 2006-06-01 Takeda Pharmaceutical Company Limited Dérivé d’acide arylalcanoïque
JP5415271B2 (ja) 2006-10-11 2014-02-12 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害剤としての置換ピロロ−ピラゾール誘導体
ITMI20071731A1 (it) 2007-09-06 2009-03-07 Univ Degli Studi Genova Nuovi derivati ureici dell'acido 1h-pirazol-4-carbossilico con attivita inibente nei confronti della chemiotassi di neutrofili
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
BRPI0910921B1 (pt) 2008-04-16 2022-06-21 Portola Pharmaceuticals, Inc Inibidores de proteína syk quinase, composição farmacêutica, kit e usos dos referidos inibidores
EP2271631B1 (fr) 2008-04-22 2018-07-04 Portola Pharmaceuticals, Inc. Inhibiteurs de protéines kinases
CA2639003A1 (fr) 2008-08-20 2010-02-20 Canadian Blood Services Inhibition de la phagocytose provoquee par des substances de type fc.gamma.r au moyen de preparations a teneur reduite en immunoglobuline
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
CA2792278C (fr) 2010-04-13 2019-05-14 Rigel Pharmaceuticals, Inc. Composes 2,4-pyrimidinediamine et leurs promedicaments, et leurs utilisations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011042798A1 (fr) * 2009-10-08 2011-04-14 Incozen Therapeutics Pvt. Ltd. Dérivés de pyrazole en tant que modulateurs du canal calcique activé par la libération de calcium et méthode de traitement pour le cancer du poumon à cellules non petites
WO2011092140A1 (fr) * 2010-01-27 2011-08-04 Boehringer Ingelheim International Gmbh Composés pyrazole comme antagonistes du crth2

Non-Patent Citations (30)

* Cited by examiner, † Cited by third party
Title
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 14 June 2009 (2009-06-14), "1H-Pyrazole-4,5-diamine, N5-[(1-ethyl-2-pyrrolidinyl)methyl]-1,3-dimethyl-", XP002751500, Database accession no. 1157040-74-8 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 14 June 2009 (2009-06-14), "1H-Pyrazole-5-methanamine, N-[(1-ethyl-2-pyrrolidinyl)methyl]-1-methyl-", XP002751499, Database accession no. 1157110-36-5 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2 November 2011 (2011-11-02), "1H-Pyrazole-4,5-diamine, 1,3-dimethyl-N5-[(1-methyl-1H-pyrazol-5-yl)methyl]-", XP002751494, Database accession no. 1339733-80-0 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 22 November 2009 (2009-11-22), "1H-Pyrazole-5-methanamine, N-[(1-ethyl-2-pyrrolidinyl)methyl]-1,3-dimethyl-", XP002751497, Database accession no. 1193211-04-9 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 22 November 2009 (2009-11-22), "1H-Pyrazole-5-methanamine, N-[(1-ethyl-2-pyrrolidinyl)methyl]-1-phenyl-", XP002751498, Database accession no. 1193182-10-3 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 24 April 2011 (2011-04-24), "1H-Pyrazol-4-amine, 1,3-dimethyl-5-[2-(1-methyl-2-pyrrolidinyl)ethoxy]-", XP002751495, Database accession no. 1284856-24-1 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 27 February 2012 (2012-02-27), "1H-Pyrazole, 1-methyl-5-[[1-methyl-3-(1,1,2,2,2-pentafluoroethyl)-1H-pyrazol-5-yl]oxy]-3-(1,1,2,2,2-pentafluoroethyl)-4-(trifluoromethyl)-", XP002751493, Database accession no. 1357625-31-0 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 4 March 2008 (2008-03-04), "1H-Pyrazole-5-methanamine, 1-ethyl-N-[(1-propyl-1H-pyrazol-5-yl)methyl]-", XP002751511, Database accession no. 1006466-59-6 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 4 March 2008 (2008-03-04), "1H-Pyrazole-5-methanamine, 1-methyl-N-(1-methyl-1H-pyrazol-5-yl)-", XP002751516, Database accession no. 1006459-42-2 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 4 March 2008 (2008-03-04), "1H-Pyrazole-5-methanamine, 1-methyl-N-(1-methyl-1H-pyrazol-5-yl)-3-(trifluoromethyl)-", XP002751514, Database accession no. 1006460-38-3 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 4 March 2008 (2008-03-04), "1H-Pyrazole-5-methanamine, 1-methyl-N-[(1-methyl-1H-pyrazol-5-yl)methyl]-", XP002751517, Database accession no. 1006447-59-1 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 4 March 2008 (2008-03-04), "1H-Pyrazole-5-methanamine, 1-methyl-N-[(1-methyl-1H-pyrazol-5-yl)methyl]-3-(trifluoromethyl)-", XP002751512, Database accession no. 1006466-43-8 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 4 March 2008 (2008-03-04), "1H-Pyrazole-5-methanamine, 1-methyl-N-[(1-propyl-1H-pyrazol-5-yl)methyl]-", XP002751513, Database accession no. 1006466-39-2 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 4 March 2008 (2008-03-04), "1H-Pyrazole-5-methanamine, N-(1-methyl-1H-pyrazol-5-yl)-1-propyl-", XP002751515, Database accession no. 1006459-91-1 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 4 March 2008 (2008-03-04), "1H-Pyrazole-5-methanamine, N-[(1-ethyl-1H-pyrazol-5-yl)methyl]-1-methyl-", XP002751509, Database accession no. 1006480-46-1 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 4 March 2008 (2008-03-04), "1H-Pyrazole-5-methanamine, N-[(1-ethyl-1H-pyrazol-5-yl)methyl]-1-methyl-3-(trifluoromethyl)-", XP002751510, Database accession no. 1006466-62-1 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 6 April 2011 (2011-04-06), "1H-Pyrazole-4-methanamine, 1,3-dimethyl-5-[2-(1-methyl-2-pyrrolidinyl)ethoxy]-", XP002751496, Database accession no. 1275824-05-9 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 7 March 2008 (2008-03-07), "1H-Pyrazole-5-methanamine, 1-cyclopentyl-N-(1-methyl-1H-pyrazol-5-yl)-", XP002751507, Database accession no. 1006957-56-7 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 7 March 2008 (2008-03-07), "1H-Pyrazole-5-methanamine, 1-ethyl-N-(1-methyl-1H-pyrazol-5-yl)-", XP002751508, Database accession no. 1006957-03-4 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 7 March 2008 (2008-03-07), "1H-Pyrazole-5-methanamine, 1-ethyl-N-(1-methyl-1H-pyrazol-5-yl)-3-(trifluoromethyl)-", XP002751501, Database accession no. 1006958-11-7 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 7 March 2008 (2008-03-07), "1H-Pyrazole-5-methanamine, 1-ethyl-N-[(1-ethyl-1H-pyrazol-5-yl)methyl]-", XP002751504, Database accession no. 1006957-80-7 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 7 March 2008 (2008-03-07), "1H-Pyrazole-5-methanamine, 1-ethyl-N-[(1-ethyl-1H-pyrazol-5-yl)methyl]-3-(trifluoromethyl)-", XP002751502, Database accession no. 1006957-90-9 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 7 March 2008 (2008-03-07), "1H-Pyrazole-5-methanamine, 1-ethyl-N-[(1-methyl-1H-pyrazol-5-yl)methyl]-3-(trifluoromethyl)-", XP002751505, Database accession no. 1006957-65-8 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 7 March 2008 (2008-03-07), "1H-Pyrazole-5-methanamine, N-[(1-cyclopentyl-1H-pyrazol-5-yl)methyl]-1-ethyl-", XP002751503, Database accession no. 1006957-85-2 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 7 March 2008 (2008-03-07), "1H-Pyrazole-5-methanamine, N-[(1-cyclopentyl-1H-pyrazol-5-yl)methyl]-1-methyl-", XP002751506, Database accession no. 1006957-60-3 *
FUSCO R ET AL: "Sintesi e proprieta farmacologiche di composti pirazolici", FARMACO,, vol. 23, 1 January 1968 (1968-01-01), pages 919 - 944, XP009187424, ISSN: 0014-827X *
LUPO B ET AL: "Synthese et proprietes ionophores de coronands heterocycliues. I. Macrocycles a unites monopyrazoliques", BULLETIN DE LA SOCIETE CHIMIQUE DE FRANCE, SOCIETE FRANCAISE DE CHIMIE. PARIS, FRANCE, vol. 2, no. 11-12, 1 January 1984 (1984-01-01), pages 464 - 472, XP009187422, ISSN: 0037-8968 *
PUROHIT MEENA K ET AL: "Disulfide linked pyrazole derivatives inhibit phagocytosis of opsonized blood cells", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 23, no. 8, 26 February 2013 (2013-02-26), pages 2324 - 2327, XP028525209, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2013.02.064 *
REVILL P ET AL: "Eltrombopag", vol. 31, no. 9, 1 January 2006 (2006-01-01), pages 767 - 770, XP002696072, ISSN: 0377-8282, Retrieved from the Internet <URL:http://journals.prous.com/journals/servlet/xmlxsl/dof/20063109/pdf/df310767.pdf?p_JournalId=2&p_refId=1030939&p_IsPs=N> [retrieved on 20151126], DOI: 10.1358/DOF.2006.031.09.1030939 *
See also references of WO2014138979A1 *

Also Published As

Publication number Publication date
US20190022066A1 (en) 2019-01-24
US11090288B2 (en) 2021-08-17
EP2970138B1 (fr) 2019-01-16
CA2903612A1 (fr) 2014-09-18
CA2903612C (fr) 2021-03-30
WO2014138979A1 (fr) 2014-09-18
US20160022640A1 (en) 2016-01-28
EP2970138A1 (fr) 2016-01-20
DK2970138T3 (en) 2019-03-25
US10130609B2 (en) 2018-11-20

Similar Documents

Publication Publication Date Title
EP2970307A4 (fr) Composés pyrazolo et leurs utilisations
EP2951177A4 (fr) Composés imidazopyridine et leurs utilisations
EP3236972A4 (fr) N4-hydroxycytidine, ses dérivés et utilisations anti-virales
EP2968337A4 (fr) Composés hétéroaryle et utilisations associées
EP2991978A4 (fr) Composés bihétéroaryle et leurs utilisations
DK2763112T3 (da) Dynamisk nødhjælp
EP2968259A4 (fr) Concentrés bioactifs et leurs utilisations
EP2970505A4 (fr) Anticorps bispécifiques et leurs utilisations
ME03063B (fr) Inhibiteurs de ssao 3-halogénoallylamines substituées et leurs utilisations
EP2771020A4 (fr) Dérivés n-acyldipeptides et leurs utilisations
BR302013004852S1 (pt) Configuração aplicada em auto-falante
EP2888238A4 (fr) Composés benzocyclo-octyne et leurs utilisations
EP2885318A4 (fr) Conjugués peptides-dendrimères et leurs utilisations
EP2967046A4 (fr) Derives de benzimidazole et leurs utilisations
EP2958895A4 (fr) Composés thérapeutiques et leurs utilisations
EP2968107A4 (fr) Compositions cosmétiques et leurs utilisations
DK3054068T3 (da) Foldelås
EP2956138A4 (fr) Composés thérapeutiques et utilisations de ceux-ci
EP2953978A4 (fr) Conjugés de phosphorylcholine et leurs utilisations
EP2956141A4 (fr) Nouvelles utilisations
EP3383401A4 (fr) Dérivés de thiéno-pyrimidine et utilisations de ceux-ci
EP3080142A4 (fr) Compositions glycopeptidiques et leurs utilisations
EP3373924A4 (fr) Formulations topiques et leurs utilisations
EP2970895A4 (fr) Cultures de podocytes et leurs utilisations
EP2822601A4 (fr) Microarn et leurs utilisations

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150902

A4 Supplementary search report drawn up and despatched

Effective date: 20151211

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20161123

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20180406

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CANADIAN BLOOD SERVICES

Owner name: UNIVERSITY HEALTH NETWORK

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20180608

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: UNIVERSITY HEALTH NETWORK

Owner name: CANADIAN BLOOD SERVICES

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602014040031

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1089603

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190215

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20190318

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: VALIPAT S.A. C/O BOVARD SA NEUCHATEL, CH

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1089603

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190116

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190116

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190116

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190116

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190116

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190116

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190416

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190516

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190516

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190416

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190116

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190116

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190116

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602014040031

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190116

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190116

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190116

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190116

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190116

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190116

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190116

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190312

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190116

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20190331

26N No opposition filed

Effective date: 20191017

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190312

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190116

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190312

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190116

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20140312

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190116

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190116

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240315

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240306

Year of fee payment: 11

Ref country code: GB

Payment date: 20240229

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20240313

Year of fee payment: 11

Ref country code: FR

Payment date: 20240308

Year of fee payment: 11

Ref country code: DK

Payment date: 20240314

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20240401

Year of fee payment: 11

P01 Opt-out of the competence of the unified patent court (upc) registered

Free format text: CASE NUMBER: APP_36489/2024

Effective date: 20240618